Bottom line
ACLAX vs IJR: the short answer
ACLAX (Mid Cap Value Fund) and IJR (iShares Core S&P Small-Cap ETF) are both mutual funds.
But IJR is far broader, holding 683 positions to 134 for ACLAX, so beyond the top names it adds exposure ACLAX doesn't have.
IJR is cheaper at 0.06% vs 1.23% — a difference of $117 a year per $10,000 invested.
Over five years, IJR returned +7.2% a year vs +7.2% for ACLAX.
ACLAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
ACLAX vs IJR side by side
| ACLAX | IJR | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | American Century | iShares |
| Category | Mid-Cap | Small-Cap |
| Expense ratio | 1.23% | 0.06% |
| Annual cost per $10k | $123 | $6 |
| 10-yr cost on $10k (prospectus) | $1,978 | $77 |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +2.4% | +5.9% |
| 5-yr return (annualized) | +7.2% | +7.2% |
| 10-yr return (annualized) | +8.1% | +9.8% |
| Best quarter | — | +31.3% |
| Worst quarter | — | −32.7% |
| Net assets (fund) | $5.6B | $111.3B |
| Number of holdings | 134 | 683 |
| Portfolio turnover | 62% | 25% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
ACLAX and IJR share none of their top holdings.
ACLAX top 10
- Kimberly-Clark Corp — 2.26%
- Commerce Bancshares Inc/MO — 2.01%
- Zimmer Biomet Holdings Inc — 2.01%
- Henry Schein Inc — 1.97%
- Labcorp Holdings Inc — 1.84%
- Evergy Inc — 1.67%
- Packaging Corp of America — 1.64%
- State Street Bank & Trust Co — 1.63%
- Xcel Energy Inc — 1.62%
- Becton Dickinson & Co — 1.58%
IJR top 10
- Blackrock Global — 5.45%
- Blackrock Cash Funds — 2.08%
- Formfactor Inc — 0.67%
- Viasat Inc — 0.66%
- Molina Healthcare Inc — 0.64%
- Argan Inc — 0.60%
- Brightspring Health Services Inc — 0.60%
- Element Solutions Inc — 0.59%
- Maxlinear Inc — 0.58%
- Krystal Biotech Inc — 0.53%
FAQ
What is the difference between ACLAX and IJR?
Which is cheaper, ACLAX or IJR?
Should I own both ACLAX and IJR?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.